에 대한 최신 뉴스 Hologic (NASDAQ:HOLX) 주식

Hologic

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

AMZN

HOLX

ORCL

투자자들이 경제 낙관론, 기업 실적 호조, 트럼프 행정부의 주요 정책 변화 등을 소화하면서 S&amp;P 500 지수는 1월 마지막 주에 6,100포인트를 돌파하며 사상 최고치를 경신하고 있다.

1월 마지막 주에 상승할 수 있는 S&amp;P 500 주식 5종목은?

Hologic Inc

News

Hologic Granted FDA Clearance For Aptima SARS-CoV-2 Assay

<p>Raymond James  analyst Andrew Cooper   reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Outperform and lowers the price target from $95 to $90.</p>


Price Target

Reiteration

Analyst Ratings

Raymond James Reiterates Outperform on Hologic, Lowers Price Target to $90

<p>RBC Capital  analyst Conor McNamara   maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Sector Perform and lowers the price target from $88 to $85.</p>


RBC Capital Maintains Sector Perform on Hologic, Lowers Price Target to $85

<p>Evercore ISI Group  analyst Vijay Kumar   maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a In-Line and lowers the price target from $76 to $73.</p>


Evercore ISI Group Maintains In-Line on Hologic, Lowers Price Target to $73

<p>Stephens &amp; Co.  analyst Mason Carrico   reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Overweight and maintains $84 price target.</p>


Stephens & Co. Reiterates Overweight on Hologic, Maintains $84 Price Target

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Evercore ISI Group raised <strong>Arm Holdings plc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) price target from $176 to $202. Evercore ISI Group analyst Mark Lipacis maintained an Outperform rating. Arm shares closed at $173.26 on Wednesday. <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for <strong>Amgen Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) from $256 to $275. B of A Securities analyst Tim Anderson maintained an Underperform rating. Amgen shares closed at $307.81 on Wednesday. <a href="https://www.benzinga.com/quote/AMGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital boosted <strong>Fiserv, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) price target from $233 to $260. BMO Capital analyst Rufus Hone maintained an Outperform rating. Fiserv shares closed at $229.53 on Wednesday. <a href="https://www.benzinga.com/quote/FI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt raised the price target for <strong>Coherent Corp</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) from $105 to $115. Rosenblatt analyst Mike Genovese maintained a Neutral rating. Coherent shares closed at $90.10 on Wednesday. <a href="https://www.benzinga.com/quote/COHR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Northland Capital Markets cut the price target for <strong>CSG Systems International, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGS#NASDAQ">CSGS</a>) from $78 to $80. Northland Capital Markets analyst Nehal Chokshi reiterated an Outperform rating. CSG Systems shares closed at $61.66 on Wednesday. S<a href="https://www.benzinga.com/quote/CSGS/analyst-ratings">ee how other analysts view this stoc</a>k.</li>
<li>Piper Sandler slashed <strong>Skyworks Solutions, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) price target from $85 to $70. Piper Sandler analyst Harsh Kumar maintained a Neutral rating. Skyworks shares settled at $87.08 on Wednesday. <a href="https://www.benzinga.com/quote/SWKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut <strong>PepsiCo, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) price target from $158 to $153. Barclays analyst Lauren Lieberman maintained an Overweight rating. PepsiCo shares closed at $145.66 on Wednesday. <a href="https://www.benzinga.com/quote/PEP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners cut <strong>Hologic, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) price target from $80 to $75. Leerink Partners analyst Puneet Souda downgraded the stock from Outperform to Market Perform. Hologic shares closed at $72.80 on Wednesday.  <a href="https://www.benzinga.com/quote/HOLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs raised the price target for <strong>Workday, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) from $300 to $310. Goldman Sachs analyst Kash Rangan maintained a Buy rating. Workday shares settled at $276.17 on Wednesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler slashed <strong>Uber Technologies, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) price target from $82 to $80. Piper Sandler analyst Thomas Champion maintained an Overweight rating. Uber shares closed at $64.48 on Wednesday. <a href="https://www.benzinga.com/quote/UBER/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></strong></li>
</ul>


Pre-Market Outlook

Markets

Trading Ideas

AMGN

COHR

CSGS

SWKS

UBER

WDAY

Uber To $80? Here Are 10 Top Analyst Forecasts For Thursday

<p>U.S. stock futures were higher this morning, with the Dow Jones futures gaining around 100 points on Thursday.</p>
<p>Shares of <strong>Ford Motor Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) fell sharply in today's pre-market trading after the company said that it expects $5 billion to $5.5 billion in losses in its EV segment this year, in line with the loss <a href="https://www.benzinga.com/tech/25/02/43522408/ford-slides-5-pre-market-after-disappointing-outlook-high-loss-from-ev-segment-in-2024">recorded last year</a>.</p>
<p>Ford said it sees full-year 2025 adjusted EBIT in a range of $7 billion to $8.5 billion, adjusted free cash flow in a range of $3.5 billion to $4.5 billion, and capital spending in a range of $8 billion to $9 billion.</p>
<p>Meanwhile, Ford reported upbeat fourth-quarter financial results on Wednesday.</p>
<p>Ford Motor shares dipped 6.1% to $9.40 in the pre-market trading session.</p>
<p>Here are some other stocks moving lower in pre-market trading.</p>
<ul>
<li><strong>Skyworks Solutions, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) dipped 29.2% to $61.65 in pre-market trading after the company issued second-quarter adjusted EPS guidance below estimates..</li>
<li><strong>FormFactor, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) fell 27.7% to $29.78 in today's pre-market trading after the company reported worse-than-expected fourth-quarter adjusted EPS results and issued cirst-quarter guidance below estimates.</li>
<li><strong>Matrix Service Company</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTRX#NASDAQ">MTRX</a>) shares fell 26.1% to $10.38 in pre-market trading after the company reported second-quarter financial results and cut its FY25 sales guidance below estimates.</li>
<li><strong>SunCar Technology Group Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>) fell 18.3% to $6.90 in pre-market trading after the company reported the pricing of $50 million follow-on public offering of class a ordinary shares.   </li>
<li><strong>Symbotic Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) fell 16.6% to $25.80 in pre-market trading. Symbotic reported quarterly losses of three cents per share which missed the analyst consensus estimate for losses of two cents. Quarterly revenue of $486.69 million also missed the analyst consensus estimate of $490.98 million.</li>
<li><strong>Mach Natural Resources LP</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) declined 6.9% to $16.00 in pre-market trading as the company announced the launch of 12 million common unit offering.</li>
<li><strong>Mineralys Therapeutics, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) fell 5.5% to $9.70 in pre-market trading. Mineralys Therapeutics will report its financial results from the fourth quarter, before the opening bell on Wednesday, Feb. 12.</li>
<li><strong>Hologic, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) slipped 4.9% to $69.22 in pre-market trading following quarterly results.</li>
<li><strong>QUALCOMM Incorporated</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) fell 4.7% to $167.50 in pre-market trading following first-quarter results.</li>
<li><strong>Arm Holdings plc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) fell 4.2% to $166.06 in pre-market trading. Arm Holdings reported better-than-expected third-quarter financial results for fiscal year 2025 after the market closed on Wednesday. Arm said it expects fourth-quarter revenue of $1.175 billion to $1.275 billion. The company anticipates fourth-quarter adjusted earnings of 48 cents to 56 cents per share. The company also narrowed its full-year guidance.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></strong></li>
</ul>


Movers

FORM

MLYS

MTRX

QCOM

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

Ford, Skyworks Solutions, FormFactor And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

<p>Leerink Partners  analyst Puneet Souda   downgrades Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Outperform to Market Perform and lowers the price target from $80 to $75.</p>


Downgrades

Leerink Partners Downgrades Hologic to Market Perform, Lowers Price Target to $75

WIIM

Hologic shares are trading lower after the company cut its FY25 revenue outlook.

<p>Needham  analyst Mike Matson   reiterates Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Hold to Hold.</p>


Needham Reiterates Hold on Hologicto Hold

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) reported its Q1 earnings results on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

Hologic Q1 Earnings Assessment

<p>The Q1 earnings report for <strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) was released on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>The company missed on EPS by $0.0 in the last quarter, resulting in a 6.0% drop share price change the following day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Hologic Q1

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) just disclosed its Q1 earnings on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hologic Q1 Earnings Summary & Key Takeaways

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) announced its Q1 earnings on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hologic Earnings Report: Q1 Overview

Guidance

Hologic Expects Q2 Revenue Of $995M - $1.005B (Est $1.036B), Adj EPS Of $1.00 - $1.03 ((Est $1.03)

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) just disclosed its Q1 earnings on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 6.0% drop in the share price the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hologic Earnings Review: Q1 Summary

Hologic Cuts FY25 Revenue Outlook From $4.15B - $4.20B To $4.05B - $4.10B, Est $4.162B

<p><strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) reported its Q1 earnings results on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>Last quarter the company missed on EPS by $0.0 which was followed by a 6.0% drop in the share price the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hologic: Q1 Earnings Insights

<p>The Q1 earnings report for <strong>Hologic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) was released on Wednesday, February 5, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Hologic beat estimated earnings by 1.0%, reporting an EPS of $1.03 versus an estimate of $1.02.</p>
<p>Revenue was up $9.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.</p>
<p>Here's a look at Hologic's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>1.02</td>
<td>0.98</td>
<td>0.95</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.01</td>
<td>1.06</td>
<td>1.03</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>976.69M</td>
<td>1.00B</td>
<td>1.00B</td>
<td>986.12M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>987.90M</td>
<td>1.01B</td>
<td>1.02B</td>
<td>1.01B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Hologic management provided guidance for Q2 2025, expecting earnings between $1.0 and $1.03 per share.</p>
<p>To track all earnings releases for Hologic <a href="https://www.benzinga.com/quote/HOLX/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Hologic Q1

<p>"We are reducing our full-year revenue guidance based mainly on currency headwinds and weakness in breast health capital sales, which are outweighing strength in our U.S. diagnostics business," said Karleen Oberton, Hologic's Chief Financial Officer. "At the same time, we are maintaining our full-year guidance for non-GAAP EPS based on strong profitability and execution of our capital allocation strategy."</p>


Hologic Lowers FY25 Guidance For GAAP EPS; Maintains Guidance For Adj EPS Of $4.25 - $4.35, Est $4.26

Press Releases

Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines

Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC

Hologic Completes Acquisition of Gynesonics, Inc.

Hologic to Announce Financial Results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025

Hologic to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide

Biote Announces CEO Retirement and Succession Plan

Hologic Announces Financial Results for First Quarter of Fiscal 2025

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

BTMD

MYGN

PODD

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Envista Holdings Corporation Common Stock

Envista Holdings

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Raymond James

RBC Capital

Evercore ISI Group

Stephens & Co.

Leerink Partners

<p>투자자들이 경제 낙관론, 기업 실적 호조, 트럼프 행정부의 주요 <a href="https://www.benzinga.com/topic/donald-trump" target="_blank" rel="noopener">정책 변화</a> 등을 소화하면서 S&amp;P 500 지수는 1월 마지막 주에 6,100포인트를 돌파하며 사상 최고치를 경신하고 있다.</p>
<p>이러한 시장 상승세의 중심에는 <b><strong>도널드 트럼프</strong></b>가 있다. <a href="//www.benzinga.com/government/regulations/25/01/43085323/trump-sworn-in-as-47th-president-declares-golden-age-of-america-begins-right-now"" target="_blank" rel="noopener">새로 취임한</a> 제47대 미국 대통령은 <a href="//www.benzinga.com/government/regulations/25/01/43086509/trump-unleashes-executive-orders-on-border-security-oil-drilling-domestic-manufacturing-in-first-acts-as-president"" target="_blank" rel="noopener">무역, 이민, 석유</a>를 겨냥한 일련의 행정명령으로 첫 주를 시작했다. 일부 행정명령은 즉각적인 효과가 있는 것도 있고, 상징적인 것도 있으며, 일부는 법적 문제에 <a href="https://www.npr.org/2025/01/21/g-s1-44023/trump-birthright-citizenship-immigration-order-14th-amendment">직면해 있다.</a></p>
<p>화요일에 트럼프는 5,000억 달러 규모의 프로젝트인 <a href="https://www.benzinga.com/etfs/sector-etfs/25/01/43135764/trumps-500-billion-stargate-ai-plan-puts-3-etfs-in-focus" target="_blank" rel="noopener">AI 스타게이트 계획을 공개</a>하기도 했다. 그리고 목요일, 트럼프는 다보스 <a href="https://www.youtube.com/watch?v=DKBWckduL2k" target="_blank" rel="noopener">화상 연설</a>을 통해 미국이 "인공지능과 암호화폐의 세계 수도"가 될 것이라고 선전했다.</p>
<p>한편, 조용한 흐름도 나타나고 있다. 1월 마지막 주는 역사적으로 주식에 긍정적인 시기였으며, 데이터에 따르면 몇몇 S&amp;P 500 종목이 큰 폭의 상승세를 보일 수 있다.</p>
<h3><b><strong>1월 마지막 주에 대한 낙관론 촉발</strong></b></h3>
<p>계절성이 항상 신뢰할 수 있는 시장 예측 변수는 아니지만, 패턴이 거의 한 세기 동안 지속될 때는 주의를 기울여야 한다. Seasonax의 데이터에 따르면 지난 97년 동안 1월은 평균 1.1%의 상승률로 60%의 시간 동안 플러스 영역에서 마감했다.</p>
<p>더욱 놀라운 점은 이러한 상승의 절반 이상이 월 마지막 주에 발생했다는 것다. 1928년 이후 S&amp;P 500 지수는 1월 마지막 주에 평균 0.6% 상승했으며, 61%의 기간 동안 상승 마감했다.</p>
<h3><b><strong>1월 말 상승 이력이 있는 주식 5종목</strong></b></h3>
<p>과거 패턴이 미래를 좌우하지는 않지만 종종 일치하는 경우가 있다. 20년간의 시장 데이터에 따르면 S&amp;P 500 주식 중 5개 종목이 1월 마지막 주에 꾸준히 초과수익을 기록했다.</p>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th><strong>주식</strong></th>
<th><strong>평균 수익률 (1월 마지막 주)</strong></th>
<th><strong>상승 마감 (지난 20년)</strong></th>
<th><strong>최고 성과</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>홀로직 </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>)</td>
<td><strong>4.08%</strong> (1월 23일 – 2월 2일)</td>
<td>20년 중 14년 상승</td>
<td>2005년 36.58%</td>
</tr>
<tr>
<td><strong>아마존 </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td><strong>2.7%</strong> (1월 23일 – 1월 30일)</td>
<td>20년 중 16년 상승</td>
<td>2009년 16.2%</td>
</tr>
<tr>
<td><strong>NRG 에너지</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>)</td>
<td><strong>2.5%</strong> (1월 23일 – 2월 2일)</td>
<td>20년 중 14년 상승</td>
<td>2016년 21.04%</td>
</tr>
<tr>
<td><strong>웰스파고 </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>)</td>
<td><strong>1.9%</strong> (1월 23일 – 1월 31일)</td>
<td>20년 중 13년 상승</td>
<td>2009년 21%</td>
</tr>
<tr>
<td><strong>벡톤 디킨슨 앤 코</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td><strong>1.56%</strong> (1월 23일 – 2월 2일)</td>
<td>20년 중 14년 상승</td>
<td>2005년 9.8%</td>
</tr>
</tbody>
</table>
</figure>
<p><em>이미지: Shutterstock</em></p>
<p class="p1"><em><b>다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.</b></em></p>
<p class="p2"><em><span class="s1">Benzinga Pro</span>의 독점 뉴스를 통해<span class="s1"> </span>수백만 명의 다른 트레이더보다<span class="s1"> </span>더 빠르게<span class="s1"> </span>유용한 투자 뉴스를 확인할 수 있습니다<span class="s1">. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor"><span class="s2">여기를</span> <span class="s2">클릭</span></a></span>하여<span class="s1"> 14</span>일 무료 체험을 시작하세요<span class="s1">.</span></em></p>

Comments

Hologic

뉴스

에 대한 최신 뉴스 Hologic (NASDAQ:HOLX) 주식

금요일, 1월 24, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌